Biological effectiveness of antiproton annihilation

A new experiment, AD-4/ACE (antiproton cell experiment), has been approved by the CERN Research Board. The experiment is scheduled to begin taking data in June and continue through the 2003 run cycle. The experiment is designed to determine whether or not the densely ionizing particles emanating fro...

Full description

Saved in:
Bibliographic Details
Published inNuclear instruments & methods in physics research. Section B, Beam interactions with materials and atoms Vol. 214; pp. 181 - 185
Main Authors Maggiore, Carl, Agazaryan, Nzhde, Bassler, Niels, Blackmore, Ewart, Beyer, Gerd, DeMarco, John J., Doser, Michael, Gruhn, Charles R., Holzscheiter, Michael H., Ichioka, Toshiyasu, Iwamoto, Keisuke S., Knudsen, Helge V., Landua, Rolf, McBride, William H., Møller, Søren Pape, Petersen, Jorgen, Smathers, James B., Skarsgard, Lloyd D., Solberg, Timothy D., Uggerhøj, Ulrik I., Withers, H.Rodney, Wouters, Bradly G.
Format Journal Article
LanguageEnglish
Published Elsevier B.V 2004
Subjects
Antiproton annihilation
Biological response
Bragg peak
Bragg peak
25.43
87.53
87.50
Biological response
Antiproton annihilation
Online AccessGet full text

Cover

More Information
Summary:A new experiment, AD-4/ACE (antiproton cell experiment), has been approved by the CERN Research Board. The experiment is scheduled to begin taking data in June and continue through the 2003 run cycle. The experiment is designed to determine whether or not the densely ionizing particles emanating from the annihilation of antiprotons produce an increase in “biological dose” in the vicinity of the narrow Bragg peak for antiprotons compared to protons. This experiment is the first direct measurement of the biological effects of antiproton annihilation. The background, description, and status of the experiment are given.
ISSN:0168-583X
1872-9584
DOI:10.1016/S0168-583X(03)01781-6